Gilead won’t acquire checkpoint oncology biotech Tizona

Gilead has now passed on two biotech buyout options that it forged in summer 2020.

The large drugmaker will not acquire Tizona Therapeutics, a fellow California biotech working on a new type of checkpoint therapy for certain cancers, a Gilead spokesperson confirmed to Endpoints News via email on Tuesday evening.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks